44 results
8-K
EX-3.1
ZNTL
Zentalis Pharmaceuticals Inc
15 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:12pm
or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
7.2 STOCK CERTIFICATES; PARTLY PAID SHARES.
The shares
424B5
ZNTL
Zentalis Pharmaceuticals Inc
15 Jun 23
Prospectus supplement for primary offering
4:12pm
in skin punch biopsies demonstrated active target engagement at relevant pharmacological doses. We initiated the Phase 1 monotherapy dose expansion
8-K
EX-99.2
ZNTL
Zentalis Pharmaceuticals Inc
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
) ZN-c3 100 mg/kg (qd × 4, 3 d off) Azenosertib (ZN-c3): Wee1 Inhibitor
18 3. Skin Biopsy Decreases in p-CDK1 Show Target Engagement for Wee1 … Inhibition Confirmation of Wee1 Target Engagement in Surrogate Tissue 1 1. CDK1 phosphorylation (p-CDK1) is mediated by Wee1 2. Inhibition of Wee1 will lead
8-K
EX-99.2
lbs3dt8kn
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am
8-K
EX-99.2
36fl03yc4udv mok06i
9 Aug 22
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
12:00am
424B5
gyms4rdgz2i
16 May 22
Prospectus supplement for primary offering
5:17pm
424B5
8fe37agh09baiq8
27 Apr 22
Prospectus supplement for primary offering
4:15pm
424B5
nh4ua1cfld ppcerq
30 Jun 21
Prospectus supplement for primary offering
4:51pm
424B5
lr7mje5dxp
28 Jun 21
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.2
u1b8gfklfqsh45
28 Jun 21
Other Events
7:11am
S-3ASR
9eelrjtv66r8 ua
4 May 21
Automatic shelf registration
5:29pm
S-3
a8w2e
4 May 21
Shelf registration
12:00am
DEF 14A
adbchbc
23 Apr 21
Definitive proxy
4:05pm
10-K
EX-10.12
222ev41n
25 Mar 21
Annual report
7:17am